

Policy	MM-027
Effective Date	09/01/2024
Reviewed/Revised Date	03/30/2026
Next Review Date	03/30/2027
Origination Date	07/01/2024
Originated Department	Clinical Operations

Breast Tomosynthesis

Audience

Providers, Members, Brokers, MHC

Purpose

Medical policies provide general support for applying Mountain Health Co-Op member policy document coverage decisions, and the member-specific benefit plan document must be referenced. The terms of the member-specific Policy document may differ from the standard benefit plan based on this medical policy. If there is a conflict between a member-specific policy document and the Mountain Health Co-Op medical policy, the document supersedes this policy. Any person(s) applying this medical policy must identify member eligibility, the member-specific policy document, and related policies or guidelines before applying this medical policy, including the existence of any state or federal guidance. Mountain Health Co-Op medical policies are designed for informational purposes only and are not an authorization, explanation of benefits, or contract. Receipt of benefits is subject to the satisfaction of all terms and conditions of the member-specific policy document coverage. Mountain Health Co-Op reserves the sole discretionary right to modify all policies and guidelines at any time.

Definition

Breast cancer is the most common noncutaneous cancer in women. According to the American Society of Clinical Oncology (ASCO), in 2020 the United States is estimated to have 276,480 new cases of invasive breast cancer diagnosed in women and 2,620 cases in men. An additional prediction of 48,530 new cases of non-invasive (in situ) breast cancer in women. The ASCO anticipates that in 2020, approximately 42,690 deaths (42,170 women and 520 men) from breast cancer will occur in the U.S.

Standard approaches to screening and diagnosis of breast cancer are analog or digital mammography, breast ultrasound, and breast MRI.

Mammography or full-field digital mammography (FFDM) remains the mainstay of screening for breast cancer. Mammography may detect cancer one and a half to four years before a cancer becomes clinically evident.

Tomosynthesis is a tomographic application of digital mammography. The tomosynthesis acquisition mimics conventional mammography with regard to breast positioning and compression, but unlike conventional mammography, the x-ray tube takes multiple low-dose exposures as it moves through a limited (e.g., 30°) arc of motion. The individual images are then reconstructed into a series of thin high-resolution slices that can be displayed individually or in a dynamic ciné mode, with a total radiation dose similar to conventional mammography.

Ultrasonography is commonly used for diagnostic follow-up of an abnormality seen on screening digital mammography, to clarify features of a potential lesion. Ultrasound is used to
Disclaimer: 1. Policies are subject to change in accordance with State and Federal notice requirements. 2. Policies outline coverage determinations for U of U Health Plans Commercial, CHIP and Healthy U (Medicaid) plans. Refer to the “Policy” section for more information. 3. Services requiring prior-authorization may not be covered, if prior-authorization is not obtained. 4. This Medical Policy does not guarantee coverage or payment of the service. The service must be a benefit in the member’s plan and the member must be eligible for coverage at the time of service. Additional payment guidelines may be applied that are not included in this policy. further evaluate masses or asymmetries and can differentiate a solid mass from a cyst. Ultrasonography is also used to provide guidance for biopsies and other interventions. It is the first line of imaging in a woman who is pregnant or less than thirty years old with focal breast symptoms or findings.

Ultrasonography is commonly used for diagnostic follow-up of an abnormality seen on screening digital mammography, to clarify features of a potential lesion. Ultrasound is used to
Disclaimer: 1. Policies are subject to change in accordance with State and Federal notice requirements. 2. Policies outline coverage determinations for U of U Health Plans Commercial, CHIP and Healthy U (Medicaid) plans. Refer to the “Policy” section for more information. 3. Services requiring prior-authorization may not be covered, if prior-authorization is not obtained. 4. This Medical Policy does not guarantee coverage or payment of the service. The service must be a benefit in the member’s plan and the member must be eligible for coverage at the time of service. Additional payment guidelines may be applied that are not included in this policy. further evaluate masses or asymmetries and can differentiate a solid mass from a cyst. Ultrasonography is also used to provide guidance for biopsies and other interventions. It is the first line of imaging in a woman who is pregnant or less than thirty years old with focal breast symptoms or findings.

The role of magnetic resonance imaging (MRI) for breast cancer screening is emerging. Currently MRI screening, in combination with mammography is targeted to high risk patients. Screening MRI is recommended for women with an approximately 20%-25% or greater lifetime

risk of breast cancer, including women with a strong family history of breast or ovarian cancer and women who were treated for Hodgkin's disease.

The combination of MRI and mammography is recommended by the American Cancer Society in women at high risk of breast cancer ($\geq 20\%$ to 25% lifetime risk), as defined by risk prediction models based primarily on family history. The cancer mortality risk in this population is assumed to be high enough to justify the increased cost and numbers of follow-up procedures that would be generated because of low specificity.

Policy/Procedure

Mountain Health Co-Op covers breast tomosynthesis as a screening and diagnostic modality in assessing and managing breast cancer.

1. Clinical rationale

1.1 Previous reviews of breast tomosynthesis (BT) in 2008 and 2011 failed to identify sufficient evidence for this technology to be considered proven. Since the previous review of this technology in 2011 two systematic reviews and thirteen primary literature articles have been published. The studies evaluated the results of more than 59,000 patients who underwent mammography and/or BT. The majority of the articles report taking into consideration inter-rater reliability, recall rates, cancer detection rate and study design. Since the previous review most of the primary literature articles assess similar endpoints. Both the systematic reviews and 11 of 13 (85%) of the primary literature articles used BT specifically for screening. With regard to their findings, several key endpoints are assessed – inter-rater reliability, recall rates, cancer detection and comparative outcomes to digital mammography. The following summarizes these findings on several of these areas:

- a) Inter-rater Reliability:** Kappa statistics (a statistical measure of inter-rater reliability with values between 0 and 1 where 0 is no agreement at all and 1 is complete agreement) were reported by two authors. Both of these papers compared full field digital mammography (FFDM) to BT and compared the conclusions of five radiologists when viewing each type of image. The average kappa statistic was 0.90. Where kappa statistics were not reported but where there were multiple readers, decreases in recall rates and increases in area under the curve were still identified with use of BT.
- b) Recall Rates:** Ten of the thirteen papers (77%) addressed the potential for a decrease in recall rates with the use of BT. With the exception of the Rafferty et al. paper which reported a recall reduction rate of 6-67%, from which reasonable conclusions cannot be drawn, the average recall reduction rate with the use of BT was 27.5% (range = 17.2-37%).
- c) Cancer Detection:** There was an inherent inclusion bias against tomosynthesis with respect to cancer detection in a screening population. Many cancers were acquired in patients scheduled for biopsy and had been detected on conventional mammograms as part of standard screening evaluation. It is likely that studies underestimate the potential gains in sensitivity that might occur in clinical practice. For example, the study by Gennaro et al. both cranio-caudal

(CC) and mediolateral oblique (MLO) images were acquired with FFDM but this information was compared to BT which only assessed MLO images. This in turn will decrease the sensitivity of BT as it compares to FFDM. All studies that addressed cancer detection noted an increase in detection with the use of BT. Studies varied, however, in their ability to increase cancer detection to a statistically significant degree.

- 1.2** Specific to comparative sensitivity and specificity to FFDM, all thirteen papers illustrated noninferiority to 2D mammography when used as either a screening tool or in follow-up imaging studies. These studies showed sensitivities for breast tomosynthesis ranging from 76.2% to 100% compared with 64.1% to 97.5% for FFDM. Similarly specificity for BT ranged from 74.2 to 92% in these studies compared with a range of 51% to 83% for FFDM. In those studies which looked at recall rates studies identified a reduction in recall rates ranging from 17.2% to 37%.
- 1.3** There is a degree of heterogeneity that exists between the papers that make clear and concise inferences regarding how BT will be used in routine practice difficult. Some studies used a combined technique comparing BT + FFDM to FFDM alone; some were prospective where others were retrospective; some papers assessed BT as a triage tool after FFDM had been done; some used BT as a screening tool and others used it as a diagnostic test. Overall, however, the studies demonstrated that breast tomosynthesis improved identification of clinically relevant abnormalities and reduced unnecessary biopsies or further imaging.
- 1.4** Hunter et al (2017) reported on a retrospective data analysis that was performed between July 15, 2013, and July 14, 2014, with data on women presenting for screening mammography that included any additional radiologic workup (n = 6319). Patients chose to undergo Digital Breast Tomosynthesis (DBT) or FFDM on the basis of personal preference, physician suggestion, and cost difference. 6319 patients who participated were divided: 3655 patients underwent DBT, and 2664 underwent FFDM during the year of screening. After standardization of the difference in cancer detection rates between the two groups, DBT was a cost-equivalent alternative to FFDM for private insurance billing but was a costinefficient alternative with respect to Medicare costs. In a community-based setting, DBT is a cost- equivalent or potentially cost-effective alternative to FFDM and has the capacity for improving cancer detection and recall rates.
- 1.5** Li et.al. (2018) evaluated reducing some of the limitations of digital mammography (DM), such as overlapping tissue, by adding digital breast tomosynthesis (DBT). Emerging evidence has shown that DBT increases breast cancer detection and improves assessment of screen-recalled findings. In conclusion, evidence on DBT for breast cancer screening reinforces that DBT integrated with DM increases cancer detection rates compared to DM alone.
- 1.6** The American Academy of Radiology's (ACR) 2014 statement on breast tomosynthesis announced that breast tomosynthesis has shown to be an advance over digital mammography, with higher cancer detection rates, fewer patient recalls for additional testing and improved key screening parameters compared to digital mammography.
- 1.7** The NCCN (National Comprehensive Cancer Network) guidelines for breast cancer screening and diagnosis (Version 1.2017) shows that digital breast tomosynthesis in

conjunction with two-dimensional (2D) mammography improves cancer detection and decreases call back rates.

- 1.8** The 2019 American Society of Breast Surgeon's (ASBrS) Position Statement on Screening Mammography recommends that women age >25 should undergo formal risk assessment for breast cancer. Women with an average risk of breast cancer should initiate yearly screening mammography (3D preferred modality) at age 40. Women with a higher-than-average risk of breast cancer should undergo yearly screening mammography (3D preferred modality) and be offered yearly supplemental imaging; this screening should be initiated at a risk-based age and screening mammography should cease when life expectancy is <10 years.
- 1.9** A recent UpToDate article (2020, updated in 2023) evaluated the effectiveness and harms of screening for breast cancer. When compared with digital mammography, multiple retrospective cohort and prospective clinical trials suggest that tomosynthesis modestly increases rates of cancer detection and decreases recall rates for false-positive mammography readings. Digital breast tomosynthesis may detect more breast cancers in younger women and women with extremely dense breasts. In one metaanalysis, the incremental cancer detection rate was higher with tomosynthesis than with digital mammography screening alone, with an increase of 1.6 cancers detected per 1000 screens (95% CI 1.1- 2.0). The recall rate for tomosynthesis was lower than for digital mammography alone (pooled absolute reduction -2.2, 95% CI -3.0 to -1.4). No studies have assessed the effects of tomosynthesis on breast cancer mortality. Two important clinical trials comparing screening digital mammography with tomosynthesis are ongoing: the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) in North America and the Digital Breast Tomosynthesis plus Synthesized Images versus Standard Full-Field Digital Mammography in Population-Based Screening (TOSYMA) trial in Germany.
- 1.10** In conclusion, based upon the updated published evidence, breast tomosynthesis appears to be a tool that is non-inferior to FFDM, decreases recall rates, identifies a statistically significant and nonsignificant number of breast cancers unidentifiable in FFDM and has a better area under the curve statistic than does FFDM (GRADE 1B).

Applicable Coding

CPT Codes

77061	Digital breast tomosynthesis; unilateral
77062	Digital breast tomosynthesis; bilateral
77063	Screening digital breast tomosynthesis, bilateral (List separately in addition to code for primary procedure)

HCPCS Codes

G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)
--------------	------------------------------------------------------------------------------------------------------------------

Vendors

- **Personify**
- **HPS**

References

1. Administration, F.a.D. Selenia Dimensions 3D System - P080003. 2013 May 20, 2013 [cited 2013 August 19]; Available from: <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm246400.htm>.
2. Altekruse, S., C. Kosary, and M. Krapcho. SEER Cancer Statistics Review, 1975-2007. 2009 November 2009 [cited 2010 January 10]; Available from: http://seer.cancer.gov/csr/1975_2007/browse_csr.php?section=4&page=sect_04_table.09.html.
3. American college of Radiology (ACR). (2014). ACR Statement on Breast Tomosynthesis. Accessed September 17, 2020. Available at: <https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Breast-Tomosynthesis>
4. American Society of Breast Disease. American Society of Breast Disease Statement on Digital Breast Tomosynthesis. 2013 [cited 2014 January 20].
5. American Society of Breast Surgeons (2019) Position Statement on Screening Mammography. Accessed September 17, 2020. Available at: <https://www.breastsurgeons.org/docs/statements/Position-Statement-on-Screening-Mammography.pdf>
6. American Society of Clinical Oncology (ASCO), Breast Cancer: Statistics (Jan 2018); Available at: <https://www.cancer.net/cancer-types/breast-cancer/statistics>
7. American Society of Clinical Oncology (ASCO), Breast Cancer: Statistics (July 2020); Accessed September 17, 2020. Available at: <https://www.cancer.net/cancer-types/breast-cancer/statistics>
8. Amir T, Ambinder EB, Harvey SC, Oluyemi ET, Jones MK, Honig E, Alvin MD, Mullen LA. Benefits of digital breast tomosynthesis: A lesion-level analysis. J Med Screen. 2021 Sep;28(3):311-317. doi: 10.1177/0969141320978267. Epub 2020 Dec 17. PMID: 33334233.
9. Arora, N., et al., Effectiveness of a noninvasive digital infrared thermal imaging system in the detection of breast cancer. Am J Surg, 2008. 196(4): p. 523-6.
10. Baker, J.A. and J.Y. Lo, Breast tomosynthesis: state-of-the-art and review of the literature. Acad Radiol, 2011. 18(10): p. 1298-310.
11. Beasley, J.M., et al., Alcohol and risk of breast cancer in Mexican women. Cancer Causes Control, 2010.
12. Benzon Larsen, S., et al., Interaction between ADH1C Arg(272)Gln and alcohol intake in relation to breast cancer risk suggests that ethanol is the causal factor in alcohol related breast cancer. Cancer Lett, 2010.
13. Bernardi, D., et al., Prospective study of breast tomosynthesis as a triage to assessment in screening. Breast Cancer Res Treat, 2012. 133(1): p. 267-71.
14. Brandt, K.R., et al., Can digital breast tomosynthesis replace conventional diagnostic mammography views for screening recalls without calcifications? A comparison study in a simulated clinical setting. AJR Am J Roentgenol, 2013. 200(2): p. 291- 8.
15. Carney, P.A., et al., Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med, 2003. 138(3): p. 168-75.
16. Chakrabarti, K., et al. FDA Executive Summary: Meeting of the Radiological Devices Advisory Panel; Selenia Dimensions 3D* digital breast tomosynthesis (DBT) system (P080003). 2010 September 24, 2010 [cited 2010 December 28]; Available from: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/RadiologicalDevicesPanel/UCM226661.pdf>.
17. Ciatto, S., et al., Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancet Oncol, 2013. 14(7): p. 583-9.
18. Elmore MD, JG. (2020). "Screening for breast cancer: Evidence for effectiveness and harms." UpToDate. Literature current though: September 2023. Topic last updated October 12, 2023. Available at: https://www.uptodate.com/contents/screening-for-breast-cancer-evidence-for-effectiveness-and-harms?search=digital%20breast%20tomosynthesis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H3757829

19. Ferrini, R., et al., Screening mammography for breast cancer: American College of Preventive Medicine practice policy statement. *Am J Prev Med*, 1996. 12(5): p. 340-1.
20. Fletcher, S.W., et al., Report of the International Workshop on Screening for Breast Cancer. *J Natl Cancer Inst*, 1993. 85(20): p. 1644-56.
21. Gennaro, G., et al., Performance comparison of single-view digital breast tomosynthesis plus single-view digital mammography with two-view digital mammography. *Eur Radiol*, 2013. 23(3): p. 664-72.
22. Haas, B.M., et al., Comparison of Tomosynthesis Plus Digital Mammography and Digital Mammography Alone for Breast Cancer Screening. *Radiology*, 2013.
23. Hayes, Inc. Health technology Assessment. "Digital Breast Tomosynthesis for Breast Cancer Diagnosis and Screening". Health Tech Assessment: October 24, 2017. Annual Review: December 3, 2021. Accessed August 31, 2022. Available at: <https://evidence.hayesinc.com/report/dir.digital2904> Archived: November 23, 2022.
24. Holen ÅS, Bergan MB, Lee CI, Zackrisson S, Moshina N, Aase HS, Haldorsen IS, Hofvind S. Early screening outcomes before, during, and after a randomized controlled trial with digital breast tomosynthesis. *Eur J Radiol*. 2023 Oct;167:111069. doi: 10.1016/j.ejrad.2023.111069. Epub 2023 Sep 1. PMID: 37708674.
25. Hunter, S. A., et al. (2017). "Digital Breast Tomosynthesis: Cost-Effectiveness of Using Private and Medicare Insurance in Community-Based Health Care Facilities." *AJR Am J Roentgenol* 208(5): 1171-1175.
26. Institute, N.C. SEER Stat Fact Sheets: Breast. 2013 [cited 2013 August 13]; Available from: <http://seer.cancer.gov/statfacts/html/breast.html#incidence-mortality>.
27. Kolb, G.R., Economic Implications of Breast Density and the Early Detection of Breast Cancer, 2011.
28. Kopans, D., et al., Calcifications in the breast and digital breast tomosynthesis. *Breast J*, 2011. 17(6): p. 638-44.
29. Li, T., et al. (2018). "Digital breast tomosynthesis (3D mammography) for breast cancer screening and for assessment of screen-recalled findings: review of the evidence." *Expert Rev Anticancer Ther* 18(8): 785-791.
30. Mathis, K.L., et al., Palpable presentation of breast cancer persists in the era of screening mammography. *J Am Coll Surg*, 2010. 210(3): p. 314-8.
31. Mayo Clinic Staff. Breast Cancer Definition. 2009 November 19, 2009 [cited 2010 December 20]; Available from: <http://www.mayoclinic.com/health/breast-cancer/ds00328>.
32. Michell, M.J., et al., A comparison of the accuracy of film-screen mammography, full-field digital mammography, and digital breast tomosynthesis. *Clin Radiol*, 2012. 67(10): p. 976-81.
33. Mun, H.S., et al., Assessment of extent of breast cancer: Comparison between digital breast tomosynthesis and full-field digital mammography. *Clin Radiol*, 2013. 68(12): p. 1254-9.
34. Nasui, B., et al., [Alcohol intake in relationship with the breast cancer]. *Rev Med Chir Soc Med Nat Iasi*, 2009. 113(3): p. 858- 63.
35. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer Screening and Diagnosis https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf (Accessed on July 9, 2018).
36. Niell, B. L., et al. (2017). "Screening for Breast Cancer." *Radiol Clin North Am* 55(6): 1145-1162.
37. Rafferty, E.A., et al., Assessing radiologist performance using combined digital mammography and breast tomosynthesis compared with digital mammography alone: results of a multicenter, multireader trial. *Radiology*, 2013. 266(1): p. 104-13.
38. Rose, S.L., et al., Implementation of breast tomosynthesis in a routine screening practice: an observational study. *AJR Am J Roentgenol*, 2013. 200(6): p. 1401-8.
39. Saslow, D., et al., American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin*, 2007. 57(2): p. 75-89.
40. Skaane, P., et al., Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population based screening program. *Radiology*, 2013. 267(1): p. 47-56.
41. Skaane, P., et al., Digital breast tomosynthesis (DBT): initial experience in a clinical setting. *Acta Radiol*, 2012. 53(5): p. 524-9.
42. Smith, A., Full-field breast tomosynthesis. *Radiol Manage*, 2005. 27(5): p. 25-31.
43. Society, A.C. Whats new in breast cancer research and treatment. 2013 [cited 2013 August 16]; Available from: <http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-new-research>.

44. Stevens, V.L., et al., Folate and other one-carbon metabolism-related nutrients and risk of postmenopausal breast cancer in the Cancer Prevention Study II Nutrition Cohort. Am J Clin Nutr, 2010.
45. Thibault, F., et al., Digital breast tomosynthesis versus mammography and breast ultrasound: a multireader performance study. Eur Radiol, 2013. 23(9): p. 2441-9.
46. UpToDate. (2021) Screening for breast cancer: Strategies and recommendations. Topic last updated: September 1, 2023. Literature current though September 2023.; Accessed: October 24, 2023.. Available from: http://www.uptodate.com/contents/screening-forbreast-cancer-strategies-and-recommendations?detectedLanguage=en&source=search_result&search=breast+mri&selectedTitle=2~46&provider=noProvider#H14 .
47. Wald, N.J., et al., UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. BMJ, 1995. 311(7014): p. 1189-93.
48. Yankaskas, B.C., et al., Performance of first mammography examination in women younger than 40 years. J Natl Cancer Inst, 2010. 102(10): p. 692-701.
49. Zuley, M.L., et al., Digital breast tomosynthesis versus supplemental diagnostic mammographic views for evaluation of noncalcified breast lesions. Radiology, 2013. 266(1): p. 89-95.

Review/Revision/Approval History

Date	Description
07/01/2024	NEW
03/30/2026	Reviewed and approved by Mountain Health CO-OP Policy Committee

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult appropriate healthcare providers for medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's benefit plan, effective when services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Including or excluding a procedure, diagnosis, or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as they apply to an individual member.

Mountain Health Co-Op makes no representations and accepts no liability regarding the content of any external information cited or relied upon in this policy. Mountain Health Co-Op updates its Coverage Policies regularly and reserve

es the right to amend these policies and give notice per State and Federal requirements.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Mountain Health Co-Op.

"Mountain Health Co-Op" and its accompanying logo and marks are protected and registered trademarks of Mountain Health Co-Op. The content of this Service is proprietary and protected by copyright. You may access the copyrighted content of this Service only for purposes outlined in these Conditions of Use.

